FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated monoclonal antibody which binds to nectin-4, or a fragment of said antibody, as well as a composition and a chimeric antigen receptor containing same. Also disclosed is a nucleic acid molecule coding the HC and LC sequences of said antibody or its fragment, as well as a plasmid, a cell and a cell population containing same.
EFFECT: invention is effective for treating cancer expressing nectin-4, as well as for diagnosing cancer expressing nectin-4.
30 cl, 11 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
